Navigation Links
Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Date:9/5/2007

/p>

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
(Date:5/21/2015)... 21, 2015 Tunnell Consulting, ... firm as senior statistician and Principal, a position to ... in the management and analysis of complex and large ... industries. , “We’re delighted to have Julia join the ... analytics,” said Dr. Philippe Cini, Group Vice President and ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... , , COLUMBIA, Md., Aug. ... ), today announced the signing of a Joint Development Agreement (JDA) ... The partnership combines a broad technology platform and operational capabilities to ... sugars into biodiesel. , , Under the ...
... , , , ... today announced that BD Biosciences, a segment of BD (Becton, ... Search and Pathway Navigation technologies into its new website. ... will enable its research customers to quickly and easily identify ...
... ... Spectrum Chemicals & Laboratory Products (Spectrum) announced the distribution ... increase productivity and lessen injuries due to repetitive hand crimping. ... is engineered to improve throughput in laboratories performing chromatography, analytical ...
Cached Biology Technology:BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2Spectrum Announces New Distribution of AC-Powered Tool for Crimping and Decapping of Laboratory Vials - The CRIMPenstein™ 2
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Even though organic methods may increase farm biodiversity, a ... be a better way to maintain food production and ... of butterfly populations in UK landscapes by scientists at ... organic farms have more butterflies than conventional farms, but ...
... produced a peak amount of electricity estimated at 7.4 GW, ... to previous years, this shows the EU,s dominance, where more ... installed. By the end of 2009, Europe,s cumulative installed PV ... which is about 70% of the world,s total (22GW). These ...
... on bacteria that instructs bone cells to die could be ... scientist speaking at the Society for General Microbiology,s autumn meeting ... a way of treating painful bone infections that are resistant ... aureus (MRSA). Bone disease, or osteomyelitis, affects 1 ...
Cached Biology News:Is organic farming good for wildlife? It depends on the alternative 2Is organic farming good for wildlife? It depends on the alternative 3Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3Interrupting death messages to treat bone disease 2
MOUSE ANTI DUCK IgY LIGHT CHAIN...
ANTI END CEL LUNG AG...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: